2.  A pleural effusion is an abnormal collection
of fluid in the pleural space resulting from
excess fluid production or decreased
absorption or both. It is the most common
manifestation of pleural disease.
 Hemothorax is blood in plueral space .
 Chylothorax is chyle (lymph+fat) in pleural
spcae.
 Empyema is pus in plueral space .

3. The pleural space is bordered by the
parietal and visceral pleurae. The
parietal pleura covers the inner surface
of the thoracic cavity, including the
mediastinum, diaphragm, and ribs. The
visceral pleura envelops all lung surfaces,
including the interlobar fissures. The
right and left pleural spaces are
separated by the mediastinum.

4.  The pleural space plays an important role
in respiration by coupling the movement of
the chest wall with that of the lungs in 2
ways. First, a relative vacuum in the
space keeps the visceral and parietal
pleurae in close proximity. Second, the
small volume of pleural fluid, which has
been calculated at 0.13 mL/kg of body
weight under normal circumstances, serves
as a lubricant to facilitate movement of
the pleural surfaces against each other in
the course of respirations.

5.  Pleural effusion is an indicator of an
underlying disease process that may be
pulmonary or nonpulmonary in origin and
may be acute or chronic. Although the
etiologic spectrum of pleural effusion is
extensive, most pleural effusions are
caused by congestive heart failure,
pneumonia, malignancy, or pulmonary
embolism

6.  Reduction in intravascular oncotic pressure
(eg, hypoalbuminemia due to nephrotic
syndrome or cirrhosis)
 Increased capillary permeability or vascular
disruption (eg, trauma, malignancy,
inflammation, infection, pulmonary
infarction, drug hypersensitivity, uremia,
pancreatitis)

7.  Increased capillary hydrostatic pressure in
the systemic and/or pulmonary
circulation (eg, congestive heart failure)
 Reduction of pressure in the pleural
space, preventing full lung expansion or
"trapped lung" (eg, extensive atelectasis,
mesothelioma)
 Decreased lymphatic drainage or complete
blockage, including thoracic duct obstruction
or rupture (eg, malignancy, trauma)

8.  Increased peritoneal fluid, with migration
across the diaphragm via the lymphatics or
structural defect (eg, cirrhosis, peritoneal
dialysis)
 Movement of fluid from pulmonary edema
across the visceral pleura
 Altered permeability of the pleural membranes
(eg, inflammation, malignancy, pulmonary
embolus)

9.  Pleural effusions are generally classified as
transudates or exudates, based on the
mechanism of fluid formation and pleural
fluid chemistry. Transudates result from an
imbalance in oncotic and hydrostatic
pressures, whereas exudates are the result
of inflammation of the pleura or decreased
lymphatic drainage.

10.  Transudates causes include the following:
 Congestive heart failure
 Cirrhosis (hepatic hydrothorax)
 Atelectasis - Which may be due to
malignancy or pulmonary embolism
 Hypoalbuminemia
 Nephrotic syndrome
 Myxedema
 Constrictive pericarditis

11.  Urinothorax - Usually due to obstructive
uropathy
 Cerebrospinal fluid (CSF) leaks to the pleura -
Generally in the setting of ventriculopleural
shunting or of trauma or surgery to the thoracic
spine
 Duropleural fistula - Rare, but may be a
complication of spinal cord surgery
 Extravascular migration of central venous
catheter
 Glycinothorax - A rare complication of bladder
irrigation with 1.5% glycine solution following
urologic surgery

12.  common causes of exudates include the
following:
 Tuberculosis
 Parapneumonic .
 Malignancy (most commonly lung or breast
cancer, lymphoma, and leukemia; less commonly
ovarian carcinoma, stomach cancer, sarcomas,
melanoma)
 Pulmonary embolism
 Collagen-vascular conditions (rheumatoid
arthritis, systemic lupus erythematosus )
 Pancreatitis

13.  Trauma
 Esophageal perforation
 Radiation pleuritis
 Sarcoidosis
 Fungal infection
 Intra-abdominal abscess
 Meigs syndrome (benign pelvic neoplasm with
associated ascites and pleural effusion)
 Yellow nail syndrome (yellow nails,
lymphedema, pleural effusions

14.  Drug-induced pleural disease:
 Isoniazide.
 procainamide
 hydralazine
 quinidine
 nitrofurantoin
 methotrexate

15.  The clinical manifestations of pleural
effusion are variable and often are related to
the underlying disease process:
 Dyspnea :is the most common symptom
associated with pleural effusion.
 Cough: in patients with pleural effusion is
often mild and nonproductive. More severe
cough or the production of purulent or
bloody sputum suggests an underlying
pneumonia or endobronchial lesions

16.  Chest pain :which results from pleural irritation,
raises the likelihood of an exudative etiology,
such as pleural infection, mesothelioma, or
pulmonary infarction.
 Additional symptoms
 Other symptoms in association with pleural
effusions may suggest the underlying disease
process. Increasing lower extremity edema,
orthopnea, and paroxysmal nocturnal dyspnea
may all occur with congestive heart failure.
 Night sweats, fever, hemoptysis, and weight loss
should suggest TB. Hemoptysis also raises the
possibility of malignancy, other endotracheal or
endobronchial pathology, or pulmonary
infarction. An acute febrile episode, purulent
sputum production, and pleuritic chest pain may
occur in patients with an effusion associated with
pneumonia

17. History.
Examination:
 decreased expansion.
Stony dull percussion note.
Diminished breath sounds.
Decreased tactile vocal fremitus and
resonance.
Singns of underlying disease.

18. Investigatios:
Chest radiology and
ultrasonography
Diagnostic aspiration
Additional tests.

19.  Effusions of more than 175 mL are usually
apparent as blunting of the costophrenic angle
on upright posteroanterior chest radiographs. On
supine chest radiographs, which are commonly
used in the intensive care setting, moderate to
large pleural effusions may appear as a
homogenous increase in density spread over the
lower lung fields. Apparent elevation of the
hemidiaphragm, lateral displacement of the
dome of the diaphragm, or increased distance
between the apparent left hemidiaphragm and
the gastric air bubble suggests subpulmonic
effusions.

20. Anteroposterior, upright chest radiograph
shows bilateral pleural effusions and loss of
bilateral costophrenic angles (meniscus sign).

21.  Posteroanterior, upright chest radiograph
shows isolated, left-sided pleural effusion
and loss of left, lateral costophrenic angle.

22.  Lateral decubitus films more reliably detect
smaller pleural effusions. Layering of an
effusion on lateral decubitus films defines a
freely flowing effusion and, if the layering
fluid is 1 cm thick, indicates an effusion of
greater than 200 mL that is amenable to
thoracentesis. Failure of an effusion to layer
on lateral decubitus films indicates the
presence of loculated pleural fluid or some
other etiology causing the increased pleural
density.

24.  Chest CT scanning with contrast should be
performed in all patients with an undiagnosed
pleural effusion, if it has not previously been
performed, to detect thickened pleura or signs
of invasion of underlying or adjacent structures.
The two diagnostic imperatives in this situation
are pulmonary embolism and tuberculous
pleuritis. In both cases, the pleural effusion is a
harbinger of potential future morbidity. In
contrast, a short delay in diagnosing metastatic
malignancy to the pleural space has less impact
on future clinical outcomes. CT angiography
should be ordered if pulmonary embolism is
strongly suggested

25.  A diagnostic thoracentesis should be performed
under ultrasound guide if the etiology of the
effusion is unclear or if the presumed cause of
the effusion does not respond to therapy as
expected. Relative Relative Contraindications:
 small volume of fluid (< 1 cm thickness on a
lateral decubitus film)
 bleeding diathesis or systemic anticoagulation
 mechanical ventilation
 cutaneous disease over the proposed puncture
site.

26.  Reversal of coagulopathy or
thrombocytopenia may not be necessary as
long as the procedure is performed under
ultrasound guidance by an experienced
operator.Mechanical ventilation with positive
end-expiratory pressure does not increase
the risk of pneumothorax after
thoracentesis, but it increases the likelihood
of severe complications (tension
pneumothorax or persistent bronchopleural
fistula) if the lung is punctured. An
uncooperative patient is an absolute
contraindication for this procedure.

27.  pain at the puncture site
 cutaneous or internal bleeding from laceration
of an intercostal artery or spleen/liver puncture
 pneumothorax, empyema, reexpansion
pulmonary edema, malignant seeding of the
thoracentesis tract, and adverse reactions to
anesthetics used in the procedure.
 Pneumothorax complicates approximately 6% of
thoracenteses but requires treatment with a
chest tube drainage of the pleural space in less
than 2% of cases.
 In addition, significant chronic obstructive or
fibrotic lung disease increases the risk of a
symptomatic pneumothorax complicating the
thoracentesis

28. When a pleural fluid
sample is taken it
should be analysed as
follows:

29.  the tests first proposed by Light have
become the criterion standards:
 The fluid is considered an exudate if any of
the following are found:
 Ratio of pleural fluid to serum protein
greater than 0.5
 Ratio of pleural fluid to serum LDH greater
than 0.6
 Pleural fluid LDH greater than two thirds of
the upper limits of normal serum value

30.  The fluid is considered a transudate if all of
the above are absent
 alternative criteria:
 Pleural fluid LDH value greater than 0.45 of
the upper limit of normal serum values
 Pleural fluid cholesterol level greater than 45
mg/dL
 Pleural fluid protein level greater than 2.9
g/dL
 Pleural fluid cosidered exudate if protein
content is more than 35g/l and transudate
if less than 25g/l.

31.  The criteria from Light and these alternative
criteria identify nearly all exudates
correctly, but they misclassify approximately
20-25% of transudates as exudates, usually in
patients on long-term diuretic therapy for
congestive heart failure (because of the
concentrating effect of diuresis on protein
and LDH levels within the pleural space).

32.  Using the criterion of serum minus pleural
protein concentration level of less than 3.1
g/dL, rather than a serum/pleural fluid ratio
of greater than 0.5, more correctly identifies
exudates in these patients.
 A gradient of serum albumin to pleural fluid
albumin of less than 1.2 g/dL also identifies
an exudate in such patients.

33.  Pleural fluid LDH levels greater than 1000
IU/L suggest empyema, malignant effusion,
rheumatoid effusion, or pleural
paragonimiasis.
 Pleural fluid LDH levels are also increased in
effusions from Pneumocystis jiroveci
(formerly, P carinii) pneumonia. The
diagnosis is suggested by a pleural
fluid/serum LDH ratio of greater than 1, with
a pleural fluid/serum protein ratio of less
than 0.5. ???????????

34.  Pleural fluid glucose and pH A low pleural glucose
concentration (30-50 mg/dL) suggests malignant
effusion, tuberculous pleuritis, esophageal rupture, or
lupus pleuritis.
 A very low pleural glucose concentration (ie, < 30
mg/dL) further restricts diagnostic possibilities, to
rheumatoid pleurisy or empyema.
 Pleural fluid pH is highly correlated with pleural fluid
glucose levels. A pleural fluid pH of less than 7.30
with a normal arterial blood pH level is caused by the
same diagnoses as listed above for low pleural fluid
glucose. However, for parapneumonic effusions, a low
pleural fluid pH level is more predictive of
complicated effusions (that require drainage) than is
a low pleural fluid glucose level. In such cases, a
pleural fluid pH of less than 7.1-7.2 indicates the
need for urgent drainage of the effusion, while a
pleural fluid pH of more than 7.3 suggests that the
effusion may be managed with systemic antibiotics
alone.

35. Indications of thoracostomy in
parapneumonic effusion:
a low pleural fluid glucose level (<40
mg/dL), a low. or
pleural fluid pH (<7.2) or
 a positive Gram stain or
Positive culture of the pleural fluid
are more likely to require tube
thoracostomy.

36.  In malignant effusions, a pleural fluid pH of
less than 7.3 has been associated in some
reports with more extensive pleural
involvement, higher yield on cytology,
decreased success of pleurodesis, and
shorter survival times.
 Handle pleural fluid samples as carefully as
arterial samples for pH measurements, with
fluid collected in heparinized syringes and
ideally transported on ice for measurement
within six hours.

37.  Pleural fluid lymphocytosis, with lymphocyte
values greater than 85% of the total
nucleated cells, suggests TB, lymphoma,
sarcoidosis, chronic rheumatoid pleurisy.
 Pleural lymphocyte values of 50-70% of the
nucleated cells suggest malignancy
 Pleural fluid eosinophilia with values
greater than 10% of nucleated cells, is seen
in approximately 10% of pleural effusions and
is not correlated with peripheral blood
eosinophilia.and is most often caused by air
or blood in the pleural space.

38.  Blood in the pleural space causing
eosinophilia may be the result of pulmonary
embolism with infarction or benign asbestos
pleural effusion or may be associated with
other nonmalignant diseases, including
parasitic disease (especially paragonimiasis),
fungal infection (coccidioidomycosis,
cryptococcosis, histoplasmosis), and a variety
of medications.
 High neutrophil count in pleural fluid
suggests parapneumonic effusion.

39.  Cytology findings(abnormal mesothelial cell)
are positive in 58% of effusions related to
mesothelioma.
 The sensitivity of cytology is not highly
related to the volume of pleural fluid tested.
Sending more than 50-60 mL of pleural fluid
for cytology does not increase the yield of
analysis.

40.  Additional specialized tests are warranted
when specific etiologies are suspected.
 Pleural biopsy.
 Measure pleural fluid amylase levels if a
pancreatic origin or ruptured esophagus is
suspected or if a unilateral, left-sided
pleural effusion remains undiagnosed after
initial testing. note, increased pleural fluid
amylase can also be seen with malignancy.
 Measure triglyceride and cholesterol levels in
milky pleural fluids when chylothorax or
pseudochylothorax is suspected.

41.  Tumor markers, such as carcinoembryonic
antigen, are suggestive of malignant
effusions (especially adenocarcinoma).
 Consider immunologic studies, including
pleural fluid antinuclear antibody(SLE) and
rheumatoid factor (RA), when collagen-
vascular diseases are suspected.

42.  Transudative effusions are managed by treating
the underlying medical disorder. However,
regardless of whether transudative or exudative,
large, refractory pleural effusions causing severe
respiratory symptoms can be drained to provide
symptomatic relief.
 The management of exudative effusions depends
on the underlying etiology of the effusion.
Pneumonia, malignancy, and TB cause most
exudative pleural effusions. Complicated
parapneumonic effusions and empyemas should
be drained to prevent development of fibrosing
pleuritis. Malignant effusions are usually drained
to palliate symptoms and may require
pleurodesis to prevent recurrence.

43. Surgery :
pesistanat collections
+pleural thickning on u/s
may require surgical
intervention.

44. THANK YOU